Akouos downgraded by BofA Securities with a new price target
$AKUS
Specialty Chemicals
Consumer Discretionary
BofA Securities downgraded Akouos from Buy to Neutral and set a new price target of $20.00 from $24.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/29/2022 | $12.00 | Outperform | William Blair |
BOSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Aaron Tward, M.D., Ph.D., as chief scientific officer. Dr. Tward is a surgeon and a scientist with deep experience in genetics, genomics, gene delivery, high-throughput sequencing technologies, and the clinical care of patients with conditions of the ear and skull base. Dr. Tward was previously a member of the Akouos scientific advisory board since 2018. As chief scientific officer, he will lead the research team, and provide strategic scie
BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Stacy Price as chief technical officer. Ms. Price brings to Akouos more than 25 years of experience managing clinical and commercial biotechnology manufacturing and technical operations for a wide range of therapeutic modalities, including gene therapy. At Akouos, she will be responsible for the strategy and operations of vector development and manufacturing, as well as device development and engineering. "We are excited to welcome Stacy to
BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Dr. Kathy Reape as chief development officer. Dr. Reape brings over 20 years of experience in the pharmaceutical industry, including significant gene therapy translational and development expertise, to Akouos. "We welcome Dr. Reape to the Akouos team at this exciting time in the company's growth, as we continue to advance the AK-OTOF and AK-antiVEGF programs towards our planned IND submissions in 2022," said Manny Simons, Ph.D., M.B.A., co-f
William Blair initiated coverage of Akouos with a rating of Outperform and set a new price target of $12.00
HC Wainwright & Co. initiated coverage of Akouos with a rating of Buy and set a new price target of $25.00
BofA Securities downgraded Akouos from Buy to Neutral and set a new price target of $20.00 from $24.00 previously
SC 13G/A - Akouos, Inc. (0001722271) (Subject)
SC 13G/A - Akouos, Inc. (0001722271) (Subject)
SC 13G/A - Akouos, Inc. (0001722271) (Subject)
15-12G - Akouos, Inc. (0001722271) (Filer)
EFFECT - Akouos, Inc. (0001722271) (Filer)
POS AM - Akouos, Inc. (0001722271) (Filer)
-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the third quarter ended September 30, 2022 and provides business highlights. "This has been a transformative year for us, and we've achieved
Submitted IND for AK-OTOF to FDA Continued progress toward planned IND submission for AK-antiVEGF Presented new nonclinical data at ASGCT supporting the proposed clinical development of AK-OTOF and highlighting strategies for regulated gene expression in the inner ear Received a notice of allowance from USPTO for claims covering compositions, including AK-OTOF, and methods of treatment useful for OTOF-mediated hearing lossEnded Q2 2022 with a strong cash position of $192.9 million BOSTON, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing los
- Continued progress toward planned IND submissions for AK-OTOF in the first half of 2022 and AK-antiVEGF in 2022 - Presenting new nonclinical data at ASGCT supporting the planned clinical development of AK-OTOF and highlighting the potential use of microRNA target sites in AAV vectors for regulated gene expression in the inner ear - Presented new nonclinical data at ARO demonstrating potential of precision genetic medicine platform to address a broad range of inner ear conditions -Ended the first quarter with a strong cash position of $209.1 million BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potenti
INDIANAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Akouos, Inc. (NASDAQ:AKUS). The acquisition expands Lilly's efforts in genetic medicines to include Akouos's portfolio of potential first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss. "Akouos brings more top-tier talent and an important pipeline to Lilly's Institute for Genetic Medicine that will further accelerate our work to advance genetic medicines for people living with difficult-to-treat diseases," said Andrew C. Adams, Ph.D., senior vice president of genetic medicine
INDIANAPOLIS and BOSTON, Nov. 30, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Akouos, Inc. (NASDAQ:AKUS) today announced that the tender offer to purchase all of the issued and outstanding shares ("Shares") of Akouos's common stock in exchange for (a) $12.50 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding, plus (b) one non-tradable contingent value right ("CVR") per Share, which represents the contractual right to receive contingent payments of up to $3.00 per CVR, net to the stockholder in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones (the "Offer"), expire
-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial -Continued progress toward planned IND submission for AK-antiVEGF in 2023 -Announced on October 18 definitive agreement for Eli Lilly and Company to acquire Akouos BOSTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ:AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today reports financial results for the third quarter ended September 30, 2022 and provides business highlights. "This has been a transformative year for us, and we've achieved
4 - Akouos, Inc. (0001722271) (Issuer)
4 - Akouos, Inc. (0001722271) (Issuer)
4 - Akouos, Inc. (0001722271) (Issuer)
Although US stocks closed mixed on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Live Nation Entertainment The Trade: Live Nation Entertainment, Inc. (NYSE:LYV) Director Jimmy Iovine acquired a total of 13,74
Akouos (NASDAQ:AKUS) reported quarterly losses of $(0.54) per share. This is a 19.4 percent increase over losses of $(0.67) per share from the same period last year.
Upgrades According to Raymond James, the prior rating for Fortis Inc (NYSE:FTS) was changed from Market Perform to Outperform. In the second quarter, Fortis showed an EPS of $0.45, compared to $0.45 from the year-ago quarter. The stock has a 52-week-high of $51.66 and a 52-week-low of $34.76. At the end of the last trading period, Fortis closed at $37.76. According to UBS, the prior rating for BanColombia SA (NYSE:CIB) was changed from Sell to Neutral. For the second quarter, BanColombia had an EPS of $1.78, compared to year-ago quarter EPS of $1.28. The current stock performance of BanColombia shows a 52-week-high of $45.98 and a 52-week-low of $23.97. Moreover, at the end of the last tra